Robert W. Baird Lowers Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target to $20.00

Enanta Pharmaceuticals (NASDAQ:ENTA) had its price objective decreased by Robert W. Baird from $26.00 to $20.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Robert W. Baird’s target price would suggest a potential upside of 126.50% from the stock’s current price.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of Enanta Pharmaceuticals in a research note on Thursday, October 10th. JMP Securities restated a “market outperform” rating and issued a $21.00 price objective (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday. JPMorgan Chase & Co. decreased their target price on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a research note on Tuesday, August 6th. Finally, Evercore ISI raised shares of Enanta Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, August 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Enanta Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $19.50.

Enanta Pharmaceuticals Stock Up 3.2 %

NASDAQ ENTA opened at $8.83 on Tuesday. The firm has a market cap of $187.11 million, a P/E ratio of -1.61 and a beta of 0.56. The company’s 50 day moving average is $10.92 and its 200-day moving average is $12.30. Enanta Pharmaceuticals has a 12-month low of $8.00 and a 12-month high of $17.80.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC purchased a new position in shares of Enanta Pharmaceuticals in the second quarter valued at $35,000. US Bancorp DE boosted its stake in Enanta Pharmaceuticals by 4,933.7% during the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after buying an additional 4,243 shares during the period. State Board of Administration of Florida Retirement System purchased a new stake in shares of Enanta Pharmaceuticals during the first quarter valued at $118,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Enanta Pharmaceuticals during the third quarter valued at $122,000. Finally, Quest Partners LLC boosted its stake in shares of Enanta Pharmaceuticals by 511.2% during the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 9,692 shares during the period. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.